.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Fish and Richardson
US Army
AstraZeneca
US Department of Justice
Express Scripts
Harvard Business School
Merck
Chinese Patent Office
Federal Trade Commission

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,579,855

« Back to Dashboard

Summary for Patent: 4,579,855

Title: Melfloquin hydrochloride
Abstract:Mefloquin hydrochloride in the form of modification E as characterized by IR spectrum and X-ray diffraction pattern, as well as a process for the preparation thereof by treating mefloquin hydrochloride, comprising at least partially another modification, that is, mefloquin hydrochloride which is not pure mefloquin hydrochloride in the form of modification E, with methanol and/or ethanol, in the presence of less than 30 volume/percent of water.
Inventor(s): Bomches; Helmut (Aesch, CH), Hardegger; Bruno (Riehen, CH)
Assignee: Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:06/655,813
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,579,855

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland5459/83Oct 07, 1983

International Patent Family for Patent: 4,579,855

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria55387► Subscribe
Bulgaria60836► Subscribe
Germany3482926► Subscribe
European Patent Office0137375► Subscribe
JapanH0255432► Subscribe
JapanS60105675► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Accenture
US Department of Justice
Cerilliant
Express Scripts
Johnson and Johnson
Covington
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot